Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tumour pain16.32.03.0030.001533%
Ulcer08.03.06.0010.000358%-
Upper gastrointestinal haemorrhage07.12.02.006; 24.07.02.024--
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Uterine cancer16.12.05.001; 21.07.02.0030.000168%-
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vasculitis10.02.02.006; 24.12.04.0270.000336%
Vena cava thrombosis24.01.10.0010.000112%-
Ventricular hypertrophy02.04.02.0120.000112%-
Vision blurred06.02.06.007; 17.17.01.010--
Visual acuity reduced06.02.10.012; 17.17.01.0110.000336%
Vitreous detachment06.09.01.002; 12.01.04.0050.000224%-
Vitreous floaters06.09.01.0050.001310%
Vomiting07.01.07.0030.027098%
Weight decreased13.15.01.005--
White blood cell count decreased13.01.06.012--
Xanthoma14.08.04.010; 23.03.03.0470.000381%-
Xerosis08.01.03.0160.000168%-
Yellow skin08.01.03.046; 09.01.01.009; 23.03.03.0420.001175%-
Pneumoperitoneum07.07.01.0080.000280%-
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.018---
Cardiotoxicity02.11.01.009; 12.03.01.0070.000560%-
Intracardiac thrombus02.11.01.017; 24.01.05.0030.000112%-
Onychoclasis23.02.05.0050.000112%-
Performance status decreased08.01.03.0420.000224%-
Peripheral swelling02.05.04.015; 08.01.03.053---
Localised oedema02.05.04.006; 08.01.07.011; 14.05.06.0090.000246%
Brain oedema12.01.10.010; 17.07.02.0030.000336%
Weight fluctuation14.03.02.0020.000246%-
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 21 Pages